Browsing Tag
TEPEZZA
4 posts
Viridian Therapeutics (VRDN) challenges Amgen’s Tepezza with broader thyroid eye disease approval
Viridian Therapeutics wins FDA approval for Lumvoa, its first commercial product, challenging Amgen in thyroid eye disease.
Amgen (AMGN) stock in focus as subcutaneous TEPEZZA Phase 3 data strengthens thyroid eye disease franchise
Amgen’s Phase 3 subcutaneous TEPEZZA win could reshape thyroid eye disease treatment and competition. Read what it means for AMGN now.
Amgen to acquire Irish biopharma company Horizon Therapeutics for $28bn
Amgen through its wholly-owned subsidiary Pillartree has agreed to acquire Ireland-based biopharmaceutical firm Horizon Therapeutics for an enterprise…
Horizon Therapeutics announces $3.05bn acquisition of Viela Bio to expand rare disease pipeline
In a major move to strengthen its leadership in rare diseases, Horizon Therapeutics, an Irish biopharmaceutical company, has…